Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
Paxlovid consists of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating, and ritonavir, which slows down nirmatrelvir’s breakdown to help it remain in the body for a longer period at higher concentrations
This ninth update of WHO’s guideline on therapeutics includes a recommendation that casirivimab-imdevimab not be used for patients infected with the Omicron variant
Scientists worldwide have started employing wastewater analysis as an efficient and cost-effective approach for assessing the dynamics of the virus in a population. Several scientific methods are being developed to rapidly decode the message carried by sewage
110 BDS graduates admitted in week one of the launch
Vonjo is the first approved therapy to specifically address the needs of adult cytopenic myelofibrosis patients
The method shows the removal of seven types of PFAS – even when all of them are found in the same unit of fluid – at a level of efficiency that approaches 90%, and it does so within a few minutes
Eubio Isoquercetin derived from Sophora Japonica is expected to deliver more Quercetin to the body via small doses of Isoquercetin.
Tamper evident caps with incorporated RFID technology offer a significant reduction in RFID implementation costs
Boehringer Ingelheim plans to study this novel investigational therapy in patients with progressive fibrosing interstitial lung diseases
Subscribe To Our Newsletter & Stay Updated
